More than hot flashes: Women raise awareness about menopause symptoms and work
It took five years for Crystal Burke to put a name to the symptoms that haunted her. Heart palpitations. Insomnia so severe ...
Genentech gets FDA acceptance for its Lupus treatment's license application
Genentech, a Roche Group company(OTCQX:RHHBY) said on Wednesday that the U.S. FDA accepted the company’s supplemental ...
Lupus Foundation of America1d
FDA Accepts Supplemental Biologics License Application for Gayzva for Treatment of Lupus Nephritis
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental Biologics License Application (sBLA) for ...
Genentech receives FDA acceptance for Gazyva sBLA
Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application for Gazyva ...
Standard-Journal1d
FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
In people with lupus nephritis, Gazyva demonstrated a complete renal response benefit, a meaningful clinical outcome linked to preservation of kidney function, and slowing or prevention of end-stage ...
Medscape1d
FDA Okays Tenecteplase for Acute Ischemic Stroke
Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the standard 60-minute infusion of alteplase.
Healio2d
FDA approves TNKase for acute ischemic stroke in adults
The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...
Contract Pharma2d
Genentech’s TNKase Approved by FDA for Treatment of Strokes
The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...
News-Medical.Net2d
FDA approves Genentech’s TNKase® in acute ischemic stroke in adults
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment ...
FiercePharma14d
Genentech, Novartis join forces to raise awareness of food allergies’ impact on families
Genentech and Novartis have teamed up with Food Allergy Research & Education (FARE) to enhance the safety of children with food allergies. The launch of the initiative, which is informed by survey ...
mskcc.org15d
In Early-Phase Pancreatic Cancer Clinical Trial, Investigational mRNA Vaccine Induces Sustained Immune Activity in Small Patient Group
The phase 1 study tested autogene cevumeran (BNT122, RO7198457), a therapeutic mRNA cancer vaccine developed and researched through a collaboration between BioNTech, an immunotherapy company, and ...
Food Allergy Research & Education15d
FARE Teams Up with Genentech and Novartis to Launch Food Allergy Educational Initiative
“To that end, we are pleased to announce our relationship with Genentech and Novartis as part of a broad educational initiative to advance our mission to support patients along their journey and ...